]>
IRCT20181113041638N1 IRCT 2019-02-19 Esfahan University of Medical Sciences Effectiveness of Matoride in Attention deficit - Hyperactivity disorder Survey on short-acting methylphenidate (Ritalin) vs. long-acting methylphenidate (Matoride) effectiveness on Attention deficit Hyperactivity Disorder symptom among 6 - 18 year-old children 2019-02-20 anticipated 75 Complete https://irct.ir/trial/35193 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method: Randomization block, randomization unit: Individual, Random layer: not done Randomization, tool: Random sequence generation software (Excel), How to create random sequence: Using random blocks, each block contains 4 people And assign a number from 1 to 6 to each block, Blinding description: In this study, patients are not aware of the drug and the drug is given to them by the collector in sealed packages. The packets will be properly coded by the researcher before being available to the data collector. The drug distributor will also not be aware of the medication in the package. 3 Attention deficit - Hyperactivity disorder. Intervention 1: Intervention group: A group in which patients will receive 10 mg per day of Ritalin Manufactured by NOVARTIS every morning before the school for ten days. Intervention 2: Intervention group 2: A group of patients will receive 18 mg per day of Matoride manufactured by SALUTAS PHARMA GMBH every morning before the school for ten days. Yes - There is a plan to make this available What will be shared: All data will be available. When: The start of the access time is immediately after the relevant article is publish. To whom: All people can access the data. Conditions: All analyzes needed can be done on data, and all individuals can apply for data. Where to obtain: Applicants can contact the phone number 09138325471 to receive the data How to obtain: The data will be available to the applicant as soon as possible. Comments:
public Dr. Mohammad Javad Tarahi
Behavioral Sciences Resaerch Center, Isfahan University of Medical Sciences, Isfahan, Iran
Esfahan Iran (Islamic Republic of) 8174673441 +98 31 3792 3071 tarrahi_mj@yahoo.com Esfahan University of Medical Sciences scientific Dr. Mohammad Javad Tarahi
Behavioral Sciences Resaerch Center, Isfahan University of Medical Sciences, Isfahan, Iran
Esfahan Iran (Islamic Republic of) 8174673441 +98 31 3792 3071 tarrahi_mh@yahoo.com Esfahan University of Medical Sciences Iran (Islamic Republic of) Confirm the diagnosis of ADHD based on DSM-5 by pediatric psychiatrist Abscence of other major psychiatric disorder Being at least the age of 6 and maximum age of 18 years old Satisfaction of the inclusion by the parent or guardian of the patient 6 years 18 years Both The lack of cooperation of the patient and family in order to make the full intervention Receive other drugs, except Matoride and Ritalin A medical condition that prevents use of the drugs Severe hypersensitivity to the drug F90.9 Attention-deficit hyperactivity disorder, unspecified type Treatment - Drugs Treatment - Drugs Intervention group: A group in which patients will receive 10 mg per day of Ritalin Manufactured by NOVARTIS every morning before the school for ten days. Intervention group 2: A group of patients will receive 18 mg per day of Matoride manufactured by SALUTAS PHARMA GMBH every morning before the school for ten days. The child's performance. Timepoint: every day after school will be evaluate. Method of measurement: Parents' Conners' questionnaire. Esfahan University of Medical Sciences Approved 2018-10-04 Ethics Commitee of Isfahan University of Medical Sciences Ethics Commitee of Isfahan University of Medical Sciences, Research Vice Department, Isfahan Medical University, Hezar Jarib university, Isfahan, Iran. Esfahan Isfehan Iran (Islamic Republic of)